Amendments to the Specification:

Page 1, line 25:

IFN-con~~rSIFN-co~~ is a new interferon molecule constructed with the

Page 1, line 29:

it. IFN-con~~rSIFN-co~~ had been proved to have broad-spectrum IFN

Page 1, line 32:

Inc. addresses treatment IFN-con~~rSIFN-co~~. Chinese Patent No.

Page 1, line 33-34:

97193506.8 by Amgen, Inc. addresses re-treatment of ~~rSIFN-co~~ consensus interferon on hepatitis C. Chinese Patent No. 98114663.5 by

Page 1, line 35-36:

Shenzhen Jiusheng Bio-engineering Ltd. addresses ~~treatment of rSIFN-co~~recombinant human consensus interferon-α treatment ~~on~~ for hepatitis B and hepatitis C.

Page 2, line 1:

authorized Amgen to produce ~~rSIFN-co~~INFERGEN® (interferon alfacon-1) with *E. Coli*. for

Page 4, lines 4 and 5:

Figure 1. rSIFN-co cDNA sequence (~~Seq. ID No.~~SEQ ID NO:[[ ]]1) designed according to *E. Coli*. codon usage and deduced rSIFN-co amino acid sequence (~~Seq. ID No.~~SEQ ID NO:2)

Page 4, line 7:

Figure 2. Sequence of another super-compound interferon (~~Seq. ID Nos.~~SEQ ID NOS: 3&4)

Page 4, line 15:

Figure 6-A. Circular Dichroism spectrum of ~~Infergen~~INFERGEN® (interferon alfacon-1)

On page 4, please delete the paragraph beginning at line 23 and insert the following paragraph in its place:

INFERGEN® (interferon alfacon-1), made by Amgen Inc., also known as consensus interferon, is marketed for the treatment of adults with chronic hepatitis C virus (HCV) infections. It is currently the only FDA approved, bio-optimized interferon developed through rational drug design and the only interferon with data in the label specifically for non-responding or refractory patients. InterMune's sales force re-launched INFERGEN® (interferon alfacon-1) in January 2002 with an active campaign to educate U.S. hepatologists about the safe and appropriate use of INFERGEN® (interferon alfacon-1), which represents new hope for the more than 50 percent of HCV patients who fail other currently available therapies.

Page 5, line 1:

Figure 6-B. Circular Dichroism spectrum of ~~Infergen~~INFERGEN® (interferon alfacon-1) From Reference [Journal of Interferon and Cytokine Research. 16:489-499(1996)]

Page 5, line 22:

Clearly, as evidenced by the above spectra, the secondary or even tertiary structure of rSIFN-co is different from ~~Infergen~~INFERGEN® (interferon alfacon-1).

Page 14, line 24:
Oligomer A (~~Seq. ID No.~~SEQ ID NO:5):

Page 14, line 27:
Oligomer B (~~Seq. ID No.~~SEQ ID NO:7):

Page 14, line 30:
Oligomer C (~~Seq. ID No.~~SEQ ID NO:8):

Page 14, line 33:
Oligomer D (~~Seq. ID No.~~SEQ ID NO:9):

Page 15, line 2:
Oligomer E (~~Seq. ID No.~~SEQ ID NO:10):

Page 15, line 5:
Oligomer F (~~Seq. ID No.~~SEQ ID NO:11):

Page 16, line 11:
Oligomer G (~~Seq.ID.No.~~SEQ ID NO:[[ ]]12) :
5'ATCGGCCATATGTGCGACCTGCCGCAGACCC3'

Page 16, line 12:
Oligomer H (~~Seq. ID. No.~~SEQ ID NO:13) :
5'ACTGCCAGGCTGCAGTTATTCTTTACGACGCAGACGTTCC3'

Page 17, line 19:
(SEQ ID NO: 14) N- Cys-Asp-Leu-Pro-Gln-Thr-His-Ser-Leu-Gly-Asn-Arg-Arg-Ala-Leu-

Page 20, line 22

rSIFN-co CDNA SEQUENCE (SEQ ID NO:1) DESIGNED ACCORDING TO E. COLI. CODON USAGE AND DEDUCED rSIFN-co AMINO ACID SEQUENCE (SEQ ID NO:2)

On page 29, please delete the paragraph beginning at line 7 and insert the following paragraph in its place:

Control drugs: IFN-α2b (Intron A) as lyophilized powder, purchased from Schering Plough. 3×10^6U each, mix to 3×10^6IU/ml with culture medium; INFERGEN® (interferon alfacon-1) (liquid solution) , purchased from Amgen, 9μg, 0.3ml each, equal to $9X10^6$IU, and mix with $9X10^6$IU/ml culture medium preserve at 4°C; 2.2.15 cell: 2.2.15 cell line of hepatoma (Hep G2) cloned and transfected by HBV DNA, constructed by Mount Sinai Medical Center.

On page 32, please delete the paragraph beginning at line 6 and insert the following paragraph in its place:

Results from Tables 1, 2 and 3 show: After maximum innocuous concentration exponent culturing for 8 days with 2.2.15 cell, the maxima is $9.0 \pm 0\times10^6$IU/ml average inhibition rate of maximum innocuous concentration rSIFN-co to HBeAg is 46.0±5.25% ($P<0.001$), IC50 is $4.54\pm1.32X10^6$IU/ml, SI is 3.96; rate to HBsAg is 44.8± 6.6%, IC50 is $6.49\pm0.42\times10^5$IU/ml, SI is 2.77. This shows that rSIFN-co can significantly inhibit the activity of HBeAg and HBsAg, but that the IFN of the contrast group and INFERGEN® (interferon alfacon-1) cannot. It has also been proved in clinic that rSIFN-co can decrease HBeAg and HBsAg or return them to normal levels.

Please replace pages 37-39 with the corresponding replacement sheets attached herein as **Exhibit A**.

Page 45, line 26:

Referring to the standard of ~~Infergen~~INFERGEN® (interferon alfacon-1) for treatment of hepatitis C and according to the ALT level and HCV-RNA test, divided the effects into three degrees: